______________________ Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2024 RESULTS • Baxter third-quarter 2024 sales totaled $3.85 billion • Third-quarter total Baxter U.S. GAAP diluted earnings per share (EPS) were $0.27 ; adjusted total Baxter diluted EPS were $0.80 , exceeding the company's previously issued guidance • Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis , reflecting growth across all segments • Third ...

Baxter International Inc. (BAX) is scheduled to release third-quarter 2024 results on Nov. 8, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 3.03%. BAX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesCurrently, the consensus estimate for revenues is pegged at $3.84 billion, indicating an improvement o ...

In its upcoming report, Baxter International (BAX) is predicted by Wall Street analysts to post quarterly earnings of $0.78 per share, reflecting an increase of 14.7% compared to the same period last year. Revenues are forecasted to be $3.84 billion, representing a year-over-year increase of 3.6%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of ...

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earning ...

The time has finally come. On September 18th, the Federal Reserve slashed rates by 50 basis points. While this has been a pretty exciting time for markets, the question now becomes what works best post-rate cut? To answer thatI am an individual value investor pursuing a bachelor's degree in Finance at Florida State University with the goal of attaining my CFA. I have a distinct passion for equity research and fundamental analysis. Regarding my approach, I have been highly influenced by Tom Hayes, Founder, C ...

Baxter International (BAX) is poised for growth, given the demand for its medically essential products, coupled with transformational actions. However, inflationary pressure remains a concern.Shares of this Zacks Rank #2 (Buy) company have lost 17.9% in the past six months against the industry's 5.8% growth. The S&P 500 Index has jumped 9% in the same time frame.BAX, with a market capitalization of $18.35 billion, is a global medical technology company providing items such as kidney-dialysis equipment, infu ...

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are ...

Baxter International, Inc. (BAX) announced the launch of its next-generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. Baxter received FDA 510(k) clearance for The Vest APX System in March 2024.The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same trusted airflow technology as the previous version, with enhanced comfort ...

The Zacks Medical – Products industry’s revenues are expected to continue its growth trajectory on the back of the robust demand for surgeries and procedures, launch of new products and expansion into new markets. An earlier-than-expected demand for respiratory products is also boosting sales. The industry players are raising the prices of their products and services to cope with the higher costs, thereby benefiting the top and bottom lines.Meanwhile, a potential rise in budgets of U.S. hospitals amid impro ...